Explore every episode of the podcast VibeCast - A Vibe Bio Podcast

In this episode, VibeCast host Ray Dogum speaks with Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, about his journey to starting the company in 2014. Insilico Medicine's mission is to extend healthy productive longevity by transforming drug discovery and development with generative artificial intelligence. Key Moments: 00:00:08 - Introduction 00:01:14 - Dr. Zhavoronkov's Journey from Computer Science to Longevity Research 00:05:24 - Application of Deep Neural Networks in Biomedical Research 00:08:33 - Overcoming Challenges in AI Adoption in Biotech 00:17:07 - Ensuring Ethical and Unbiased AI in Healthcare 00:18:32 - Importance of Safety in Drug Development 00:21:53 - FDA Regulations and Drug Approval 00:26:42 - Global Collaboration and Opportunities in Africa 00:30:03 - Democratization of AI Technology 00:35:18 - Future of Biotech and AI 00:37:22 - The Future of Longevity Research 00:37:54 - Psychological Aging 00:38:22 - Conclusion and Call to Action Guest Bio: Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and robotics platforms for drug discovery. Since 2014, he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for the generation of novel molecular structures with the desired properties and the generation of synthetic biological and patient data. He also pioneered the applications of transformers and other deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership, Insilico raised over $400 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated 18 preclinical candidates, started 6 human clinical trials, and entered Phase II with an AI-discovered novel target and AI-designed novel molecule. By 2023, 11 out of the top 20 pharmaceutical companies used a part of the Pharma.AI software suite, and the IND-stage cancer program was sold in a deal with $80 million upfront as a testament to the quality and novelty of the AI-generated molecule. Guest Links: Linkedin: https://www.linkedin.com/in/zhavoronkov/ X: https://x.com/biogerontologyAdnexi Website: https://insilico.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and AI. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech financing and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, investors, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, you will be able to discover the untapped potential of African fintech startups and how to capitalize on these emerging opportunities. Gain insights into the unique challenges that African entrepreneurs face and how venture capital can help navigate and overcome them. Key moments: 00:00:00 - Introduction 00:04:22 - Tony's Journey from Africa to the US 00:06:51 - Formative Experiences at Bessemer Venture Partners 00:10:50 - Kinfolk VC Investment Thesis and Impact 00:13:52 - State of Innovation in Africa 00:18:12 - Impact Investing 00:22:06 - Supporting Small Businesses 00:25:00 - Focus on B2B Software 00:27:41 - VC Perspectives 00:32:06 - Diversifying Risk 00:32:45 - Venture Backable Businesses 00:33:29 - Audience Engagement 00:34:15 - Conclusion and Future Opportunities Guest Bio: Toni Campbell serves as a General Partner at Kinfolk Venture Capital, a fund focused on Africa and headquartered in Lagos, Nigeria. This fund specializes in pre-seed and seed-stage investments, targeting companies led by the continent's burgeoning technology entrepreneurs. A native of Nigeria, Campbell later relocated to the U.S., where he nurtured a dedication to extending the principles of the "American Dream" to everyone, particularly the upcoming generation of African entrepreneurs. Prior to founding Kinfolk, he accumulated experience at notable investment firms, including Bessemer Venture Partners and Arcadia Funds, investing in and collaborating with a wide array of portfolio companies throughout North America, Western Europe, and Africa. A Harvard University alumnus, Toni holds a BA in Social Studies and an MBA from Harvard Business School. Beyond his professional pursuits, he has a passion for contemporary African art and harbors a lifelong ambition to try out for the Nigerian National Football Team. Guest Links: Linkedin: linkedin.com/in/oluwatonic Twitter: twitter.com/oluwatonic Instagram: instagram.com/oluwatonic Kinfolk VC Website: https://kinfolk.vc/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, investors, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Sandra Shpilberg, Co-founder and CEO of Adnexi, about using AI to develop effective strategies for biopharma key expert and digital opinion leader selection to elevate your product launch. Key moments: 00:00:07 - Introducing Sandra Shpilberg 00:01:45 - Transitioning into Biopharma 00:06:06 - Starting Adnexi 00:10:29 - Importance of Finding Key Opinion Leaders 00:14:08 - Understanding Key Opinion Leaders 00:15:22 - Identifying Key Opinion Leaders 00:18:20 - Traditional Approach to Finding Experts 00:23:15 - Pros and Cons of Digital Opinion Leaders 00:26:03 - Adnexi's Unique Approach 00:29:17 - Effective Social Media Platforms 00:30:52 - Impact of Demographics on Platform Selection 00:32:33 - Changes in Biotech Funding Environment 00:33:59 - Adapting to Market Changes 00:35:35 - Global Reach 00:36:20 - Conclusion Guest Bio: Sandra Shpilberg is the CEO & co-founder of Adnexi, a software platform that helps biopharma identify Key Opinion Leaders (KOL) and Digital Opinion Leaders (DOL) and influential HCPs who can accelerate treatment development and launch. Adnexi provides rapid, accurate, tech-enabled, customized, complete and continuously updating identification of KOLs and DOLs for any disease. Before this, Sandra was the Founder and CEO of Seeker Health, a breakthrough digital patient-finding platform, which accelerated clinical trial and patient recruitment. Seeker Health grew to enroll over 60 clinical trials in 3 years. EVERSANA acquired Seeker Health in September 2018. Prior to her entrepreneurial pursuits, Sandra held executive roles at biopharmaceutical companies, including Nora Therapeutics, and BioMarin Pharmaceutical where she led the commercial launches of NAGLAZYME and KUVAN, and advanced PALINZIQ from Phase 2 to Phase 3. She’s originally from Uruguay, speaks fluent Spanish, and brings a global and diverse approach to her work and impact. She holds a BBA in Accounting from Pace University and an MBA in Marketing and Entrepreneurial Management from The Wharton School at the University of Pennsylvania. Guest Links: Linkedin: https://www.linkedin.com/in/sandra-shpilberg-b7b334/ Twitter: https://twitter.com/SandraShpilberg Adnexi Website: https://www.adnexi.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, investors, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Roy de Souza, Founder and CEO of BreakBio, about personalized cancer vaccines. --------------------------------------

Key moments: 00:00:07 - Introduction to Vibecast 00:01:01 - Roy de Souza's Journey into Cancer Care and Biotech 00:04:21 - Exploring Theories of Cancer 00:06:32 - Problem Solving in Cancer Treatment 00:12:57 - BreakBio's Drug Pipeline 00:14:41 - Breakthrough Therapy Designation and Target Indications 00:15:33 - The Power of T Cells in Targeting Solid Tumors 00:17:48 - Combination Therapy and FDA Approval 00:20:29 - Patient Treatment Timeline 00:22:11 - Leveraging AI and Machine Learning 00:28:55 - The Importance of Colon Cancer Vaccines 00:29:42 - Funding Landscape in the Biotech Industry 00:30:44 - Seeking Partnerships 00:32:42 - Future Outlook Guest Bio: Roy de Souza is solving a big problem of our lifetimes: curing solid cancers. BreakBio uses AI/ML to find 30 targets on a patient’s cancer cells from various patient data sets especially mass spectrometry per patient (an industry first). Mass spectrometry provides accurate AI training per patient. It then manufactures a 30 peptide personalized immunotherapy which is also known as a cancer vaccine. Clinical trials in the first indication are starting this year at top academic centres like MD Anderson. Roy received a Masters in Engineering at Oxford, an MBA from the Kellogg School and worked for Elon Musk's first company. He founded ZEDO Inc. that became the 3rd largest ad server in the world and used AI to determine which user sees which ad. He sold ZEDO to Warner Bros Discovery, the world's largest media company which owns CNN and HBO. Roy became determined to get to cures when his wife was diagnosed with colon cancer in 2017. She later passed away. He has 3 young children and is moving to Miami, FL. He is also a Director of SaveGroundwater.org in India and loves skiing and audiobook Guest Links: Linkedin: http://linkedin.com/in/roydesouza Twitter: https://twitter.com/roydesouza BreakBio Website: https://breakbio.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Frank Gleeson, Co-Founder and CEO of Satellos Bioscience, about groundbreaking small molecule therapies for Duchenne muscular dystrophy. -----------------------------------------------------------

Key moments: 00:00:05 - Introducing Satellos Bioscience 00:03:26 - Stem Cells and Duchenne Muscular Dystrophy 00:09:15 - Potential Treatment for Duchenne Muscular Dystrophy 00:13:22 - Research Discovery and Company Formation 00:15:59 - Clinical Trial Planning and Future Development 00:17:33 - Company Inflection Points 00:19:08 - Drug Impact and Potential 00:20:10 - Potential Indications 00:22:38 - Funding and Financial Strategy 00:24:35 - Biotech Ecosystem and Growth Guest Bio: During his career, Mr. Gleeson has been a key party to building more than 20 biomedical companies from breakthrough research and technologies and has negotiated numerous financing and M&A transactions valued in excess of $500 million. Prior to co-founding Satellos, he and Dr. Rudnicki co-founded Verio Therapeutics, where Mr. Gleeson was CEO and managed the acquisition by Fate Therapeutics (Nasdaq: FATE). Previous to Verio, he was Chief Commercial Operations at Centre for Probe Development and Commercialization (CPDC), where he played a principal role in building a global radiopharmaceutical manufacturing business and supporting the creation of two spin-out companies. Prior to CPDC, he served as an Executive-in-Residence with the Fight Against Cancer Innovation Trust (FACIT), an innovative nucleator, where he supported or led the creation, financing and exits of three new entities. Previously, Mr. Gleeson was founding CEO of MDS Proteomics Inc., where he made and integrated three acquisitions, built leading-edge sequencing infrastructure, a 200-person team, and raised in excess of $100 million. He was also Senior Vice President and Venture Partner with MDS Capital Corp. (now Lumira), where he was lead partner on a fund with more than $250 million under management focused on creating drug discovery companies based on novel Canadian science. Prior to his tenure with MDS, he enjoyed a 17-year operational career with ICI plc (now AstraZeneca), a global chemicals, pharmaceuticals, and advanced materials company, during which he was involved in technology commercialization in several fields both in Canada and internationally. Mr. Gleeson has served on numerous boards of private and public companies and not-for-profit entities. Guest Links: Linkedin: https://ca.linkedin.com/company/satellos-bioscience-inc Satellos Bioscience Twitter: https://twitter.com/satellosbio Satellos Bioscience Website: https://satellos.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Dr. Alex Federation, Co-Founder and CEO of Talus Bioscience, about leveraging machine learning to unlock the potential of the undruggable genome for groundbreaking therapies. ----------------------------------------------------- Key moments: 00:00:06 - Introduction to Vibecast 00:01:01 - Background and Early Inspiration 00:05:55 - Tackling the Undruggable Genome 00:09:14 - Specific Work in the Pipeline 00:13:26 - Leveraging AI in Biotech 00:15:09 - Using Machine Learning for Drug Development 00:16:40 - Leveraging Epigenome Profiling Data 00:17:18 - Seeking Partnerships for Drug Development 00:18:53 - Current Fundraising and Biotech Economy 00:21:33 - Tackling the Undruggable Problem Guest Bio: Alex Federation, Ph.D. is the co-founder and CEO of Talus Bio. Dr. Federation invented the MARMOT platform during his postdoctoral fellowship at the Altius Institute for Biomedical Research in Seattle where he trained in computational epigenomics and cancer biology with John Stamatoyannopoulos and Fyodor Urnov. Prior to that, Dr. Federation received his Ph.D. in chemical biology from Harvard, training with Jay Bradner in drug development for genome regulators. Guest Links: Linkedin: https://www.linkedin.com/in/afederation/ Talus Bio Twitter: https://twitter.com/talusbio Talus Bio Website: https://talus.bio/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Rahul Chaturvedi, Founder and CEO of Clora, about rethinking biotech's operating model, how AI is revolutionizing biotech innovation, and more. ------------------------------ Key moments: 00:00:06 - Introducing Vibecast 00:02:35 - Biotech 2050 Podcast 00:06:48 - Clora's Vision 00:09:52 - Uberification of Life Sciences Experts 00:13:40 - Nurturing Talent in Biotechs 00:15:50 - Flexible Work Arrangements in Biotech 00:17:23 - Accessing Top Tier Talent in Biotech 00:18:29 - The Role of AI in Biotech 00:20:52 - Career Advice in Biotech 00:22:20 - Evolution of the Boston Biotech Scene Guest Bio: Rahul Chaturvedi is the Founder and CEO of Clora, the leading marketplace where people go to discover, build, and manage on-demand life science teams. Prior to founding Clora in 2017, Rahul was the head of clinical development at several biopharma companies, such as Kaleido Biosciences (NSDQ: KLDO) and Avedro (acquired by Glaukos). Rahul has successfully led the development activities for 20+ Phase II/III programs that have resulted in 6 product approvals to date. Rahul holds a bachelor of science degree from Brandeis University. Guest Links: Linkedin: https://www.linkedin.com/in/rahulchaturvedi/ Twitter: https://twitter.com/rahulc Clora Website: https://www.clora.com/ Biotech2050 Podcast: https://on.soundcloud.com/icFqc About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Max Shapiro, CEO of PeopleConnect and PitchForce, about the questions investors want answered before they will invest and how to build a great startup team. ------------------------------------------------- Key moments: 00:00:06 - Introduction to Vibecast 00:00:47 - Max Shapiro's Background 00:03:33 - Impact of COVID-19 00:08:51 - The Influence of AI and Technology 00:10:28 - Supporting Startups and Examples 00:14:20 - Supporting Startups 00:15:56 - Importance of Team in Investments 00:18:21 - Innovations in Due Diligence 00:20:29 - Future of Investor Partnerships 00:24:40 - Embracing Entrepreneurship Guest Bio: Max is the founder and CEO of PeopleConnect, bringing remarkable energy, a rare blend of experience, a sense of creativity, and a tenaciousness that has made it possible for many startups and established companies to add key talent to their teams. A lifelong entrepreneur, a consummate networker and a business strategist, Max understands the minds and passions of startups and companies focused on growth. Max has always been an expert in finding talent; he was the youngest talent scout in the history of the NBA, serving as Chief Scout for the Phoenix Suns. He owned and operated a company that produced sports camps for children, and baseball and basketball fantasy camps for adults, where he partnered with some of the biggest names in sports, including Mickey Mantle, Willie Mays, Pat Riley, Magic Johnson, John Wooden, and Billy Casper. Max founded PeopleConnect in 1999, where he currently focuses on business development and client relations. He is an active member of several angel investment groups, and his passion for finding talent extends to introducing PeopleConnect clients to the professional resources they need to bring their company to the next level. Guest Links: Linkedin: https://www.linkedin.com/in/maxshapiro/ PeopleConnect Website: https://peopleconnect.us/ PitchForce Website: https://pitch-force.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with William Smith, PhD, Senior Fellow of Pioneer Institute, about the 340B Drug Program and its challenges. --------------------------------------------------

Key moments: 00:00:06 - Intro 00:06:16 - Impact of the Inflation Reduction Act (IRA) 00:10:19 - Orphan Cures Act and its Implications 00:13:19 - 340B Drug Program and its Challenges 00:13:32 - Tie-in to "Rationing Medicine" Book 00:14:53 - Issues with the 340B program 00:15:33 - Transparency and Reform 00:17:57 - The Quality Metric 00:20:53 - Single Payer System and Innovation 00:23:50 - Future of Biopharma Guest Bio: Dr. William S. Smith is Senior Fellow & Director of Pioneer Life Sciences Initiative. Bill has 25 years of experience in government and in corporate roles. His career includes senior staff positions for the Republican House leadership on Capitol Hill, the White House Office of National Drug Control Policy, and the Massachusetts Governor’s office where he served under Governors Weld and Cellucci. He spent ten years at Pfizer Inc as Vice President of Public Affairs and Policy where he was responsible for Pfizer’s corporate strategies for the U.S. policy environment. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies. Dr. Smith earned his PhD in political science with distinction at The Catholic University of America Guest Links: Linkedin: https://www.linkedin.com/in/william-smith-phd-54628b18/ Pioneer Institute Website: ttps://pioneerinstitute.org Rationing Medicine Book: https://pioneerinstitute.org/pioneer-research/life-sciences-pioneer-research/new-book-highlights-the-negative-impacts-of-controversial-qaly-value-assessment-framework-on-patient-access-affordability/. About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Omid Moghadam, Founder & CEO of Namida Lab, about the remarkable journey and the profound impact Namida Lab is making in diagnosing breast cancer from tears. Omid's insights into leveraging tears as a unique biomarker for cancer detection are truly eye-opening! ------------------------------------------------------- Key moments: 00:00:06 - Introducing Vibecast 00:00:56 - Omid's Career Journey 00:06:31 - Namida Lab's Inspiration 00:09:42 - Challenges in Tear-Based Testing 00:12:44 - Potential of Tear-Based Testing 00:15:41 - Innovative Cancer Screening 00:17:51 - Affordable Diagnostic Tests 00:21:46 - Company Fundraising Journey 00:23:25 - Seeking Partnerships 00:26:11 - Evolution of Breast Cancer Screening Guest Bio: Omid Moghadam is the founder and CEO of Namida Lab. He is an inventor, entrepreneur, venture investor, and educator. He specializes in launching new ventures with social impact in health and technology. Moghadam has inventions in medical imaging, cryptography, microprocessor design, medical devices, diagnostics, digital photography, data science, and communications. He is currently the Chairman of RAPID Dosimetry, a precision medicine company he also co-founded and a board member of The Diary Corporation. He is the past founder or co-founder of nine companies in Healthcare IT, genomics, diagnostics, and medical imaging, and has held executive positions at Intel, Eastman Kodak, and CTG-AMS Corporations. He formerly served on the advisory boards of Robert Wood Johnson Foundation, Children's Hospital Boston, and California Healthcare Foundation, and has held academic positions at Harvard Medical School Department of Biomedical Informatics, Rensselaer Polytechnic Institute Lally School of Business as well as an EIR position at UCLA. Mr. Moghadam’s past approaches to innovation have been highlighted in two books: Grabbing Lightning, and The Innovators Prescription. Omid loves art, history, languages, and travel. Most Sundays he can be found sweating over FT’s Polymath crossword puzzle. Guest Links: Linkedin: https://www.linkedin.com/in/omidmoghadam/ Namida Lab Linkedin: https://www.linkedin.com/company/namidalab/ Namida Lab Website: https://namidalab.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Bryan Vought, PhD and John McShane from the Boston Epigenics Society about advancing epigenetics and revolutionizing technology in biotech. -------------------------- Key moments: 00:00:06 - Introduction to Vibecast 00:01:47 - The Genesis of the Boston Epigenetics Society 00:04:20 - Understanding Epigenetics 00:07:52 - Value of the Boston Epigenetics Society 00:10:34 - Unique Qualities of Boston for Biotechs 00:15:34 - Job Market Trends 00:17:45 - Industry Shifts 00:18:28 - Strategic Partnerships 00:21:27 - Biotech Financing 00:24:00 - Event Promotion Guest Bios: Bryan Vought- I completed my PhD in biophysics at Syracuse University. I came to Boston in 2000 to do my post-doc research at Harvard Medical School. From there I was hired as a protein biochemist/biophysicist at Vertex Pharmaceuticals to focus on membrane proteins. Later in my career, I became Director of in vitro biology at Ring Therapeutics where we use human primary and IPSC cell models to better understand how anellovirus can be harnessed to provide genetic therapy to patients. While I was at Alkermes, I met John McShane. We were both passionate about epigenetics. The pandemic was keeping people apart, and we thought about how we might bring people together to talk about and promote epigenetics. We talked through different ideas about how we might do that. From that, the Boston Epigenetics Society was born. We would host webinars and bring together people while promoting epigenetics. John McShane has worked the last 12 years in biotech commercialization and business development focusing on epigenetic and next generation sequencing. He holds a Masters in Biotech Management from the Katz School of Science and Health at Yeshiva University and a Bachelors Degree in Molecular Biology from Lehigh University. He is currently the director of business development at Biomodal, a precision multiomics company backed by google ventures. John is a co-founder and steering committee member of the Boston Epigenetics Society. The Boston Epigenetic Society has been founded to: - Promote epigenetics and epitranscriptomics research - Foster connections between academics and industry epigenetics scientists - Help promote new methods - Create a support system for experimental epigenetics research Guest Links: Bryan Vought Linkedin: https://www.linkedin.com/in/bwvought/ John McShane Linkedin: https://www.linkedin.com/in/john-mcshane-ms-32764b39/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Rafael Rosengarten, PhD, CEO of Genialis, about biomarker discovery and drug development. ----------------------------------------------------------- Key Moments: 00:00:33 - Exploring Raphael's Background and Journey 00:04:50 - Favorite Guest on "Talking Precision Medicine" 00:07:02 - Joining Genialis as a Co-founder 00:10:18 - Genialis' Mission in Precision Medicine 00:12:04 - Evolution of Cancer and Predictive Biomarker Space 00:14:17 - Importance of AI in Biomarker Discovery 00:17:29 - Risks and Challenges in AI Drug Discovery 00:19:59 - Genialis's Competitive Advantage in AI Drug Discovery 00:22:48 - Genialis's Funding Journey 00:24:42 - Introduction to Responder ID 00:25:26 - Building a Supermodel 00:27:14 - Strategic Partnerships 00:28:34 - Setting Genialis Apart 00:31:36 - Genialis' Vision Guest Bio: Rafael leads Genialis’ effort to realize the promise of precision medicine, and to build a company that puts people first as a guiding principle. Prior to Genialis, he spent nearly 20 years in biomedical research, publishing on the evolution of innate immune systems, bioengineering of microbes, and genetics of development. Rafael co-invented the j5 DNA assembly design automation software for high-throughput molecular design and analyses (since commercialized by TeselaGen). Rafael earned his doctorate at Yale University, and conducted his postdoctoral research at Lawrence Berkeley National Laboratory, Joint BioEnergy Institute (JBEI) and Baylor College of Medicine. In his free time, Rafael enjoys beaches and mountains, coffee and kettlebells, and exploring the world with his wife and two children. Guest Links: Linkedin: https://www.linkedin.com/in/rrosengarten/ Genialis Linkedin: https://www.linkedin.com/company/genialis/ Genialis Website: https://www.genialis.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Travis Stiles, PhD, CEO of Novoron Biosciences, about Uncovering Protein Dysregulation in Neurodegenerative Disease. -------------------------------------------------------- Key moments: 00:00:00 - Introduction 00:01:14 - Career Shift to Neuroscience 00:05:19 - Founding Novoron Biosciences 00:09:07 - Drug Development Focus 00:11:53 - Clinical Studies and Drug Pipeline 00:13:07 - Understanding Alzheimer's Disease Components 00:14:08 - Targeting Amyloid and Tau Pathology 00:15:51 - Precision Drug Discovery for Tauopathy 00:17:44 - Route of Administration and Modality 00:22:28 - Strategic Partnerships and Collaborations 00:26:09 - Exploring New Frontiers in Biotech 00:27:05 - Advancements in Spinal Cord Therapy 00:27:47 - Ethical Concerns in Brain-Computer Interfaces 00:29:46 - Integration of Technologies in Biotech 00:32:08 - The Entrepreneurial Journey in Biotech Guest Bio: For more than a decade, Dr. Travis Stiles has studied the mechanisms underlying regenerative failure in the CNS. His work led to the discovery that the LRP1 receptor was a novel therapeutic target for neuronal regeneration after CNS damage or disease. To best translate his work into viable therapies, Dr. Stiles co-founded Novoron Bioscience early in 2014. Novoron's work developing drugs against LRP1 has opened the door to the discovery of an entirely new class of drugs capable of targeting LRP1 and other members of the low-density lipoprotein receptor family, which play critical roles in multiple diseases, but have been long considered untargetable by conventional means. Dr. Stiles holds a PhD in Biomedical Science from the University of California, San Diego (UCSD). His outstanding contributions have earned him recognition as a top innovator by esteemed groups such as J&J and Biocom, along with over $3 million in federal grants. Additionally, Dr. Stiles has actively served on multiple scientific review boards for the National Institute of Health and recently completed a four-year Federal Advisory Committee appointment to the Scientific Merit Review Board subcommittee for Regenerative Medicine in the Department of Veterans Affairs. Guest Links: Linkedin: http://www.linkedin.com/in/travis-stiles-00812a23 Twitter: https://twitter.com/titostiles Novoron Biosciences Twitter: https://twitter.com/NovoronBio Novoron Biosciences Linkedin: https://www.linkedin.com/company/novoron-bioscience/ Novoron Biosciences Website: https://novoron.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Jason Park, Co-Founder and CEO of Empress Therapeutics, about Finding Small Molecule Drugs Encoded in DNA. ------------------------------------------------------------------- Key Moments:

00:00:00 - Introduction                    

00:01:01 - Jason's Journey into Biotech                    

00:03:14 - Mission of Empress Therapeutics                    

00:03:49 - Small Molecules vs. Biologics                    

00:09:13 - Empress' Approach to Small Molecule Discovery 

00:16:20 -  Company Progression and Fundraising Journey 

00:19:31 -  Leveraging Nature's Chemistry

00:21:58 -  Partnerships and Accessing a Pool of Medicines

00:24:14 - Value Inflection Points and Clinical Trials                    

00:33:16 - The Opportunity of AI in Biotech                    

Guest Bio: Jason Park, PhD, is CEO and co-founder of Empress Therapeutics. He is also an Operating Partner at Flagship Pioneering and was a member of the founding team of Sonata Therapeutics, where he served as COO. Prior to joining Flagship in 2015, Jason was a core member of the Boston Consulting Group’s Health Care and Technology practices, operating out of BCG’s New York, Mumbai, and Paris offices. His projects include multiple large life science M&A opportunities and the design and implementation of a new funding model for a multinational Global Health organization focused on innovative technologies and interventions. Previously. Jason was a director at any early-stage biotech start-up focused on targeted drug delivery as well as the co-founder of an internet advertising firm. Jason earned a Ph.D., M.S., and B.S. in Biomedical Engineering from Yale University where his research focused on the use of nanotechnology for immunomodulatory purposes and culminated in the invention of and clinical use of a nanoparticle drug delivery platform. He is the author of multiple patents, book chapters, and over a dozen peer-reviewed papers in journals like Nature and Cell. Guest Links: Linkedin: https://www.linkedin.com/in/jason-park-8a3216a/ Empress Therapeutics Twitter: https://twitter.com/Empress_Tx Empress Therapeutics Linkedin: https://www.linkedin.com/company/empresstx/ Empress Therapeutics Website: https://www.empresstx.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Justin Olshavsky, General Partner of Pioneer Fund, about the Advantages of Founders Backing Founders in Biotech. ------------------------------------------------------------------------Key moments: 00:00:05 - Introduction 00:00:38 - Background and Y Combinator Experience 00:02:00 - Starting Pioneer Bio + Health Fund 00:07:25 - Responsibilities and Goals as a General Partner 00:10:22 - Excitement and Curiosity in Venture Investing 00:14:41 - The Future of Consumer Applications for Neuralink 00:16:25 - The Potential of BCIs and Other Interfaces 00:18:15 - Treating Mental Health with Neurotechnology 00:19:35 - The Ethical Responsibility of Investors 00:21:20 - Bio+Health Fund and Partnership Opportunities 00:30:48 - Excitement for Working with Next Generation of Founders 00:31:13 - Call to Action and Appreciation Guest Bio: Justin Olshavsky is a Founder and General Partner of the Pioneer Bio+Health Fund, where he invests in early stage biotechnology, life science, and healthcare companies. Please reach out if you're building in bio+health! He previously founded Voyage Bio (YC S19) at 23 years old, which was later acquired by a public medtech company. At Voyage, he pioneered a novel therapeutic using cooling to prevent brain damage during stroke. Justin was the CTO / Co-founder, and the only engineer at the company from inception to acquisition. He is an award-winning product designer and has a background in mechanical engineering and bioengineering (UC Berkeley / UCSF / Clemson). Guest Links Linkedin: https://www.linkedin.com/in/jolshavsky/ Twitter Pioneer Fund Linkedin Pioneer Fund Website About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Dawn Mattoon, PhD, CEO of Mercy BioAnalytics, about Breakthroughs in Early-Stage Cancer Detection. ------------------------------------------------------------------------ Key moments 00:00:06 - Introduction to Vibecast 00:00:43 - Background and Journey into Biotech 00:05:51 - Mercy BioAnalytics' Mission 00:06:51 - Transition to CEO 00:09:08 - Series A Financing and Investors 00:16:54 - The Importance of Velocity in Cancer Screening 00:18:07 - Challenges and Frictions in Accessing Screening Technology 00:19:57 - Addressing Friction in the Screening Process through Blood-Based Tests 00:24:04 - Partnerships and Collaboration in Cancer Screening Guest Bio: Dr. Dawn Mattoon is the Chief Executive Officer at Mercy Bioanalytics. She brings nearly 20 years of experience in the biotechnology industry and has held leadership positions in R&D, Strategy, and General Management for a series of exceptional companies including Invitrogen, Life Technologies, Thermo Fisher, and Cell Signaling Technology. Prior to joining Mercy, Dr. Mattoon served as the Senior Vice President for Clinical Diagnostics at Quanterix, where she led the development and commercialization of the company’s first two FDA authorized diagnostic tests for COVID-19, and received Breakthrough Device designations from the FDA for diagnostic tests in Alzheimer’s Disease and Multiple Sclerosis. She has developed and commercialized products across a range of proteomic and genomic technologies and is thrilled by the opportunity to bring the highly innovative Mercy Halo diagnostic test portfolio to patients. Dr. Mattoon earned her Ph.D. in Genetics with a focus in signal transduction from Yale University, where she also completed her postdoctoral fellowship. Dawn and her husband of 27 years, Scott, are ten-year residents of greater Boston where they enjoy hiking, paddling, and occasional visits from their children Ryland (Junior, Davidson College), and Avery (Sophomore, Emory University). Guest Links: Linkedin: https://www.linkedin.com/in/dawn-mattoon-792511a/ Mercy BioAnalytics Linkedin: https://www.linkedin.com/company/mercy-bioanalytics/ Mercy BioAnalytics Website: https://mercybio.com/

About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments.

Follow Vibe Bio's Socials:

• ⁠⁠⁠Twitter⁠⁠⁠
• ⁠⁠LinkedIn⁠⁠⁠
• ⁠⁠⁠Instagram⁠⁠⁠
• ⁠⁠⁠TikTok⁠⁠⁠
• ⁠⁠⁠Facebook⁠⁠⁠

Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Jon Chee, Co-Founder and CEO of Excedr, about Lab Equipment Financing Strategies for Biotechs. ------------------------------------------------------------------------ Key moments: 00:00:06 - Introduction 00:01:39 - Inspiration from Teachers 00:04:27 - Frustrations in the Lab 00:07:00 - Founding Excedr 00:09:10 - Traditional vs Independent Leasing Companies 00:16:23 - Types of Equipment Needed at Different Stages 00:18:55 - Shared Equipment and Facilities 00:19:30 - Industry Inflection Points 00:23:57 - The Biotech Startup Podcast 00:33:14 - Importance of Tech Transfer 00:34:22 - Building a Cohesive Team 00:36:07 - Going from Zero to One 00:36:40 - Key Considerations for Early Stage Biotech Companies 00:38:03 - Final Thoughts and Contact Information Guest Bio: Jon Chee is the CEO and Co-founder of Excedr, and has spent more than a decade working in the life sciences industry. Before founding Excedr, he spent his academic career in molecular toxicology wet labs at the University of California, Berkeley. During his time in the lab, Jon realized that his research could easily slow down or grind to a halt if there wasn't access to proper laboratory equipment. With this bottleneck in mind, he began brainstorming with a friend and soon-to-be Co-founder about possible solutions for researchers. The lack of access to mission critical instrumentation eventually led to the founding of Excedr. Excedr is a laboratory support program that provides scientists with cutting-edge instrument leases and comprehensive coverage plans at an affordable price. Excedr's goal is simple: save researchers time and money. They replace the high cost and inconvenience of buying and maintaining lab equipment with a smarter, more efficient means of conducting research. Guest Links: Linkedin: https://www.linkedin.com/in/jonchee/ The Biotech Startups Podcast: https://www.thebiotechstartupspodcast.com/ Excedr Twitter: https://twitter.com/ExcedrInc Excedr Linkedin: https://www.linkedin.com/company/excedr/ Excedr Website: https://www.excedr.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments.

Follow Vibe Bio's Socials:

• ⁠⁠Twitter⁠⁠
• ⁠LinkedIn⁠⁠
• ⁠⁠Instagram⁠⁠
• ⁠⁠TikTok⁠⁠
• ⁠⁠Facebook⁠⁠

Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Ashish Diwan, Founder and CEO of Cartago, about revolutionizing back pain treatment. --------------------------------------------------------------------------- The key moments in this episode are: 00:00:05 - Introduction to Vibecast and Guest Introduction 00:01:00 - Dr. Diwan's Background and Career 00:05:05 - The Importance of Cartilage in Development and Growth 00:08:43 - The Formation of Cartago and its Potential 00:15:39 - The Impact of Back Pain on Productivity and Society 00:16:32 - Cartago's Therapy as a Solution for Back Pain 00:18:55 - Clinical Research Plans for Cartago's Therapy 00:21:03 - Company Structure and Investment Plans Guest Bio: A surgeon and scientist, Dr. Ashish Diwan has pursued molecular therapies to speed up tissue healing. He was awarded the Merrill Lynch Global innovation award for his Doctoral work and also the prestigious Phillip D Wilson award when at Hospital for Special Surgery, Cornell University. Both awards were for single molecule strategies for fracture repair (Nitric oxide) and for spinal fusion (rhBMP-2). His work using a recombinant protein CBT005 received the very prestigious Basic Science award from the International Society for the Study of Lumbar Spine (ISSLS) and is the key molecule being commercialized by Cartago Biotech. Guest Links: Ashish Diwan Linkedin: https://www.linkedin.com/in/ashish-diwan-74366316/ Ashish Diwan Twitter: https://twitter.com/DrAshishDiwan Cartago Linkedin: https://www.linkedin.com/company/cartago-biotech/ Cartago Website: https://cartago-biotech.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials:

• ⁠Twitter⁠
• LinkedIn⁠
• ⁠Instagram⁠
• ⁠TikTok⁠
• ⁠Facebook⁠

Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Andy Hall, Founder and CSO of RareCan, about mRNA Cancer Research and Development. ------------------------------------------------------------------------ Key moments: 00:00:05 - Introduction 00:00:46 - Andy's Background 00:03:31 - RareCan's Solution 00:06:05 - Current Membership 00:09:13 - Understanding Rare Cancers 00:14:43 - Introduction to Molecularly Targeted Therapies 00:15:58 - Optimism for mRNA Vaccines 00:17:27 - mRNA Vaccine Trials for Cancer Patients 00:19:35 - The Role of Bioresource Program in Cancer Research 00:23:13 - Patient Perspectives and Metaphors of Cancer 00:30:23 - The Impact of Political Instability on Investors 00:30:57 - Strategic Investors as a Solution 00:31:21 - Goals for 2023 and 2024 00:31:53 - Importance of US Partnership 00:32:23 - Conclusion and Call to Action Guest Bio: I originally trained as a physician- looking after patients with leukemia and other malignant diseases of the blood. At an early stage I became interested in how some patients responded well to treatment whilst others didn’t so I decided to spend a few months in the laboratory studying drug resistance in childhood cancer. The few months became nearly 20 years, initially as a lab-based scientist and later as the director of the Northern institute of Cancer Research in Newcastle in the North East of England. During my time working in the University I frequently had great difficulty in assembling cohorts big enough to convince journal editors, and myself, that my laboratory observations were robust. At the same time I had the privilege of discussing my work with patients and was struck by how often they were keen to take part in research but were unable to make their wishes known. When I left the public sector in 2016 I set about finding a way for patients with rare forms of cancer who want to take part in research to be put in touch with groups who are undertaking primary research or setting up clinical trials. With 3 co-founders I set up RareCan in August 2020. We have attracted funding from an enlightened group of angel investors and are about to launch another funding round in a few months time to support our rapid expansion to other markets including the US and Australia. Guest Links: Andy Hall's Linkedin RareCan Linkedin About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: Twitter LinkedIn Instagram TikTok Facebook Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Christopher Reyes, PhD and Eyram Adjogatse, PhD from Bloom Science, about Harnessing the Gut-Brain axis to Treat Neurological Disorders. --------------------------------------------------------------------- The key moments in this episode are: 00:00:05 - Introduction 00:00:56 - Background and Founding of Bloom Science 00:05:06 - Understanding the Gut-Brain Axis 00:09:23 - Developing Therapies for the Gut-Brain Axis 00:14:49 - The Origins and Utility of the Ketogenic Diet 00:16:01 - Delivery Methods for BL One and ALS Treatment One 00:16:59 - Microbiome Applications and Alternate Delivery Methods 00:17:38 - Funding History and Future Funding Plans 00:20:55 - Partnerships and Collaborations 00:29:33 - Importance of Alignment in Investor Relationships 00:30:00 - Potential Setback in Accepting Non-Traditional Biotech Investors 00:30:18 - Appreciation for the Advice 00:30:54 - Plug for Bloom Science 00:31:15 - Conclusion and Gratitude Guest Bios: Christopher Reyes, PhD: Dr. Reyes is a biophysicist and entrepreneur with a passion for creating solutions to improve our health, environment and economic sustainability. He has founded two companies focused on developing therapeutics to address serious medical needs as well as a tech company focused on connecting people and companies to socially conscious data solutions. His first company Eclipse Therapeutics, a City Hill-backed Biogen spinout focusing on cancer stem cell targeting therapeutics, resulted in a successful acquisition in 18 months. He has a Ph.D. in Biophysics at the University of California, San Francisco and B.A. in Molecular and Cell Biology, Biophysics from the University of California, Berkeley. Eyram Adjogatse, PhD: Dr. Adjogatse connects early-stage pharma R&D candidates with partners and other supporters. He ensures that new healthcare products are developed to their full potential. Having worked in pharmacy, in drug discovery research and as a consultant, he's gained a unique perspective on the challenges of bringing healthcare products to market. He's collaborated with biotech startups, Fortune 100 pharma companies and academic labs all over the world, and that's given him a better idea of the big picture. Guest Links: Christopher Reyes Linkedin Eyram Adjogatse Linkedin Bloom Twitter Bloom Linkedin About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Andrew Gray, PhD, Co-Founder and CEO at Karma Biotechnologies, about the power of immune cells to defeat cancer. ------------------------------------------------------------------------

The key moments in this episode are: 00:00:05 - Introduction, 00:00:21 - Karma Biotech's Mission, 00:02:11 - Challenges in Cell Engineering, 00:04:19 - Andrew's Background and Inspiration, 00:08:28 - Oncology and Karma's Approach, 00:14:03 - Promising Results in Microtumor Models, 00:14:59 - Moving to Mouse Models and IND Studies, 00:15:57 - Selective Partnerships and Gene Editing, 00:17:04 - Preparing Tumors for Immunotherapies, Guest Bio: Dr. Andrew Gray is an immune engineer and co-founder of Karma Biotechnologies, a Los Angeles startup on a mission to break cancer’s immune defenses from the inside out. Andrew has dedicated his career to understanding immune tolerance, particularly how cancer hijacks this natural process to protect itself from being cleared by the patient’s immune system. He received his PhD in Genetics, Molecular and Cellular Biology from USC in 2011. Since then, he’s founded and advised multiple biotech startups, and helps assess novel technologies for several venture funds. Originally from the UK, Andrew came to the US with nothing but a place at UC Berkeley and a rucksack… which the airline lost. In their spare time Andrew and his wife love showing California’s natural wonders to their energetic three-year-old daughter and mellow baby son. Guest Links: Linkedin: https://www.linkedin.com/in/andrewgrayphd/ Karma Biotechnologies Twitter: https://twitter.com/KarmaBiotech Karma Biotechnologies Website: https://karmabiotech.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Derek Brunelle, Founder and Managing Partner at Synthase Capital Partners, about Funding the Future: Biotechs Dance with Venture Debt. ------------------------------------------------------------------------ The key moments in this episode are: 00:00:06 - Introduction, 00:00:40 - Derek's Background, 00:03:00 - Venture Debt, 00:06:49 - Interest in Life Sciences Financing, 00:10:26 - Advancements in Biotech, 00:18:19 - Challenges in the Life Science Industry, 00:19:01 - Success Stories in Debt Financing, 00:22:00 - Navigating Banking Relationships, 00:25:48 - The Future of Banking, 00:28:53 - Funding Advisors and Founder Responsibility, 00:37:42 - Filtering Founders Based on LinkedIn, 00:38:35 - Minimizing Risk in Venture Capital, 00:39:40 - The Reality of Venture Capital, 00:40:56 - The Need for Change in Venture Capital, 00:42:58 - Unwinding and Rethinking Venture Capital, Guest Bio: Derek has nearly two decades of experience supporting the capital needs of innovative technology and life science companies and has originated, structured, and managed over $700 million in debt capital commitments. Prior to founding Synthase Capital Partners, Derek was an Executive Director at J.P. Morgan and Managing Director at Silicon Valley Bank. Derek is a graduate of the University of Vermont and lives in San Diego, California with his wife and three children. Guest Links:

⁠Linkedin⁠

⁠Twitter⁠⁠Synthase Website⁠

About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Richard Austin, PhD, MBA, CEO at Reglagene, about Tubulin Targeting & Advances in Brain Cancer Treatment. -------------------------------------------------------------------------------------------- 00:00:05 - Introduction, 00:03:09 - Motivation to Start Reglagene, 00:05:15 - Challenges in Brain Cancer Treatment, 00:06:26 - Market Landscape of Brain Cancer, 00:08:46 - Tubulin Therapy for Brain Cancer, 00:16:09 - Tubulin Targeting Therapies and Toxicities, 00:17:36 - Dosing Patients and FDA Approval, 00:19:02 - Funding and Market Challenges, 00:21:53 - Importance of Trust and Decision-Making, 00:27:42 - Red Flags in Investor Deals, 00:32:24 - The Importance of Resilience in Entrepreneurship, 00:33:30 - Support for Biotech Entrepreneurs, 00:34:03 - Motivational Message for Entrepreneurs, 00:34:43 - Closing Remarks Guest Bio: Richard is a visionary biotech entrepreneur and co-founder of Reglagene, spearheading the development of groundbreaking therapies for the treatment of brain diseases. With an impressive career spanning over three decades in the pharmaceutical industry, Richard brings a wealth of expertise and a deep passion for driving transformative change in healthcare. Drawing on his strong background in laboratory research and operations management, Richard has played pivotal roles across various critical aspects of the pharmaceutical industry. From drug development and testing to overseeing the business operations of pharmaceutical R&D, he has consistently delivered outstanding results and successfully advanced new products throughout his career. Motivated by a deep commitment to improving lives and revolutionizing the biotech landscape, Richard founded Reglagene, a pioneering force in developing novel therapies for brain diseases. As CEO, he leads a dedicated team in advancing the company's first therapy for the treatment of brain cancers. With his profound industry knowledge, unwavering dedication to innovation, and a proven ability to navigate complex challenges, Richard is a compelling leader at the forefront of transforming brain disease treatment. His visionary leadership is poised to shape the future of healthcare through groundbreaking therapies developed by Reglagene. Guest Links: Linkedin: https://www.linkedin.com/in/richardaustinaz/ Reglagene Website: https://www.reglagene.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Marie Louise Fjallskog & Markku Jalkanen, PhD from Faron Pharmaceuticals about Cell Therapy Technologies. ------------------------------------------------------------------------ Guest Bios: Dr. Fjällskog has over 30 years of experience in clinical oncology, translational research, and drug development. She joined Faron from Sensei Biotherapeutics (SNSE), a Nasdaq listed immuno-oncology company. As Chief Medical Officer at Sensei, she was responsible for leading clinical and development strategy and operations. She also played a key role in Sensei’s successful $152 million IPO, which closed in February 2021. Previously, she served as Vice President, Clinical Development at Merus (MRUS) and Infinity Pharmaceuticals (INFI) where she led development of multiple small molecule and immuno-oncology clinical programs. She was formerly Global Clinical Program Leader at the Novartis Institute for Biomedical Research where she led global development of oncology treatments targeting CDK4/6, BCL-2, PD-1, CSF-1 and CD73. Dr. Fjällskog holds both a Ph.D and an M.D. from Uppsala University, Sweden where she currently serves as an Associate Professor of Oncology Dr. Fjällskog also serves on the Board of Biovica, a Swedish biotech company focused on predicting the efficacy of cancer therapies via novel blood-based diagnostics and Lytix Biopharma, a clinical stage biotech developing novel cancer immunotherapies based on pioneering research in host defense peptides. Dr. Markku Jalkanen has more than 30 years of experience within biomedical research, biotech development and the biopharmaceutical industry. He was a founding member of the Company and is its CEO. In addition to his role as CEO, he is an advisor for the only active Finnish life sciences fund, Inveni Capital. Between 1996 and 2002, Dr. Jalkanen was the founding CEO and President of BioTie Therapies Corporation, which become the first publicly traded Finnish biotech company in Helsinki to become listed on the US NASDAQ. Dr. Jalkanen has published more than 130 peer reviewed scientific publications in various highly ranked international journals. Guest Links: Marie Lousie Fjallskog Linkedin: https://www.linkedin.com/in/marie-louise-fj%C3%A4llskog-93847710/ Markku Jalkanen, PhD Linkedin: https://www.linkedin.com/in/markku-jalkanen-417a804/ Faron Pharma Website: https://www.faron.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Lisa Stehno Bittel, PhD and Karthik Ramachandran about Hydrogel Delivery of Cell and Biologic Therapies. Key Moments: 00:00:06 - Introduction to Likarda and its Co-founders, 00:03:05 - Motivation and Early Success of Likarda, 00:08:49 - Pivot Towards Cell Therapies, 00:11:05 - Innovation in Hydrogel Delivery Systems, 00:12:58 - Advantages of Hydrogels for Drug Delivery, 00:15:05 - Hydrogel Technology for Drug Delivery, 00:17:07 - Differentiation from Other Hydrogel Companies, 00:18:35 - Longevity and Duration of Hydrogel Delivery, 00:19:42 - Raising Funds and Finding Investors, 00:25:07 - Future Plans and Inflection Points, 00:30:21 - The Challenges of Cell Delivery, 00:31:19 - The Importance of Hydrogels, 00:33:19 - Potential Applications for Hydrogels, 00:34:24 - Hydrogels in Space, 00:35:11 - Maintaining Company Culture, ------------------------------------------------------------------------------- Guest Bios: Lisa Stehno Bittel, PhD began her career in health care as a physical therapist. With more than 25 years of research experience in the fields of cell biology and diabetes, she has more than 80 publications in scientific journals and received more than $9 million in grant funding for her research. She is a co-inventor on 9 US patents (issued and pending) and multiple international patents. Dr. Karthik Ramachandran is Chief Business Officer & Co-Founder of Likarda, a biotech focused on developing superior cell delivery technologies to enable cell therapies to treat some of the world’s most devastating diseases. Karthik Ramachandran, a Colorado native, pursued his passion for engineering, medicine and business at the University of Kansas at Lawrence receiving a PhD in bioengineering in 2012 with a focus in tissue engineering. He is an inventor of several patented technologies and has authored a number of peer-reviewed publications. Dr. Ramachandran pursued his entrepreneurial interests, and together with his graduate mentor, Dr. Lisa Stehno-Bittel, founded Likarda in Kansas City in 2012.

Guest Links: Lisa Stehno Bittel, PhD Linkedin: https://www.linkedin.com/in/lisa-stehno-bittel-091a0360/ Karthik Ramachandran Linkedin: https://www.linkedin.com/in/kansasbioengineer/ Likarda Website: https://likarda.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Dr Richard Johnson, Founder and CSO of Upperton Pharma Solutions, about drug delivery technologies and the challenges pharmaceutical companies face when integrating new drug delivery technologies into their pipeline. The key moments in this episode are: 00:00:06 - Introduction, 00:00:42 - Richard Johnson's Background and Upperton's Beginnings, 00:03:24 - Interest in Drug Delivery Technologies, 00:04:48 - Services Provided by CDMOs, 00:07:26 - Evolution of Drug Deliver 00:15:24 - Selection of Dosage Form, 00:16:50 - Quick and Defined Development Process, 00:18:59 - Challenges in Drug Delivery Technologies, 00:21:59 - Considerations for Nasal Delivery, 00:24:28 - Upperton's Client Base, 00:28:54 - Conclusion

Guest Bio: Dr Richard Johnson graduated from York University, UK (1982) and completed his PhD at Warwick University, UK (1986). His industrial career started at Delta Biotechnology in Nottingham, UK where he worked as a Senior Scientist working on a number of recombinant human proteins. In 1994 he jointly founded Andaris Ltd, a drug delivery company that utilised spray drying to develop novel diagnostics and and drug delivery products. Andaris was acquired in 1998 and after a successful handover he left to found Upperton Pharma Solutions in 1999. Initially Upperton focussed on developing its own, novel drug delivery products but since around 2008 the company switched its focus to become a fully focussed CDMO. In late 2021, as the company expanded he brought in a new CEO to direct our continued growth and my role switched to that of Chief Scientific Officer Guest Links: Linkedin: https://www.linkedin.com/in/richard-johnson-1628111/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Ira Spector, PhD, the CEO of SFA Therapeutics, about Developing Drugs From the GI Microbiome. Guest Bio: Dr. Spector is the co-founder of SFA Therapeutics, a microbiome-derived biotech company focused on the treatment inflammatory diseases. Ira is an experienced drug developer, with over 25 years of experience. He has helped develop 33 drugs, including Enbrel, Effexor, Protonix, Prevenar-13, Mylotarg at Wyeth/Pfizer, where he was VP of Clinical Operations and Vice-Chief of Development. At Allergan he helped develop Ozurdex for Diabetic Macular Edema and Retinal Venous Occlusion, Botox for Overactive Bladder, Botox for Chronic Migraine, Juvederm XL and Botox for cerebral palsy. Prior to Wyeth, he was VP and Partner at the PA Consulting Group. Before founding SFA Therapeutics, Ira was Executive VP of Analytics & Consulting at ICON. Ira holds BS degrees in Physics and Electrical Engineering from Washington University, where he was a Langsdorf Fellow, an MBA from Drexel University, and a PhD from Rutgers University, with a focus on biostatistics and epidemiology. Guest Links: Linkedin: https://www.linkedin.com/in/ira-spector-00414310/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Alice Valder Curran, Partner at Hogan Lovells, about Novel Drug Pricing & How Consumers Impact Drug Pricing. Key moments: 00:00:00 - Introduction, 00:01:45 - No Patient Left Behind, 00:02:47 - Innovative Legal Practitioner, 00:06:19 - Challenges in Drug Pricing, 00:09:15 - Updating Pricing Policies, 00:16:28 - The Impact of the IRA on Drug Pricing, 00:17:22 - Challenges with the Orphan Drug Act, 00:19:35 - Impact on Biotech Companies, 00:21:37 - Start Thinking Early, 00:26:04 - Consumer-Driven Pricing, 00:32:45 - The Importance of the Biotechnology Industry, 00:34:00 - Advancements in Medical Therapies, 00:34:58 - Market Access and Lifecycle Management for Biotech Companies, 00:38:10 - The Role of Patient Communities Guest Bio: Alice Valder Curran is a regulatory expert, strategic business and legal advisor to multinational pharmaceutical and biotech companies. Leads commercialization, compliance, and policy matters at all stages of development. Special focus where significant public policy considerations are informed by regulatory sensitivities and strategic business priorities. Hyper-focused on innovation, collaboration, and sustainability. Converts evolving regulatory issues into opportunities, value, and competitive advantage. Designs cutting-edge regulatory pathways that bring new drug products to market -- maximizing client profits, facilitating patient access to critical therapies, and advancing important public policy objectives. Servant leader and entrepreneurial thinker. Executive leadership roles have included the firm’s International Management Committee, setting, and implementing the strategic direction and business operations for the global enterprise. Created the framework for the organization’s values and culture messaging rollout and embedment. Spearheaded and institutionalized firmwide resources and trainings on compensation, professional development, retention, and advancement. As the first leader of the organization’s newly combined Global Regulatory and Intellectual Property Practice, directed the integration of talent across Americas, EMEA, and APAC regions and sixteen legal disciplines, managed P&L, developed business development strategy, and delivered leading profitable and business growth results year-over-year. Passionate advocate and sponsor for women and diverse professionals. Drives DEI strategy and devotes energies to produce meaningful and industry-leading results in the advancement and retention of talent. Influential speaker. Inspires and motivates on leading-edge life sciences and biotech topics, as well as on leadership, business, empowerment and inclusion. Guest Links: Linkedin: https://www.linkedin.com/in/alicevaldercurran/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.

In this episode, VibeCast host Ray Dogum speaks with Laurens Kruidenier, PhD & Fabrice Chouraqui, PharmD from Cellarity about the fascinating realm of cellular-level drug discovery. The key moments in this episode are: 00:00:00 - Introduction, 00:03:54 - Traditional Drug Discovery, 00:08:06 - Cellular Level Drug Discovery, 00:09:39 - Sickle Cell Disease Example, 00:13:16 - How Cellarity's Platform Works, 00:16:23 - The Revolutionary Potential of the Platform, 00:17:21 - The Inefficiency and Cost of Drug Discovery, 00:18:43 - Efficiency and New Discoveries with the Platform, 00:22:32 - Application of the Platform to Different Diseases, 00:26:55 - Reception from Pharma Companies and Societal Impact, 00:34:09 - Creating a Scientific Community at Cellarity, 00:34:42 - The Changing Landscape of Science, 00:35:40 - Attracting Top Talent to Cellarity, 00:36:53 - Innovation in Biotech Funding, 00:39:53 - The Future of Therapeutic Research. Laurens Kruidenier Bio: Laurens Kruidenier joined Cellarity in December 2021 as CSO. Bringing over 25 years of experience in discovery research, both in academic settings as well as in the life sciences industry, Laurens leads the continued evolution of Cellarity’s platform and pipeline. Laurens also oversees cross functional integration across all aspects of computation, drug discovery and optimization and he contributes to reinforce Cellarity’s external presence in the scientific and investor community. Laurens holds an M.Sc. in Medical Biology from Utrecht University and a Ph.D. in Mucosal Immunology from Leiden University, both in the Netherlands. In his spare time, Laurens enjoys modern & contemporary art, 1970s movies, hiking, sailing, and black & white photography. Fabrice Chouraqui Bio: Fabrice Chouraqui joined Flagship Pioneering in 2020, where he serves as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity. He has deep experience across the business spectrum, from R&D to commercial leadership, business development and investor communications. Fabrice was formerly the President of Novartis Pharmaceuticals in the US. Throughout his career at Novartis and Bristol-Myers Squibb, he has led the launch of breakthrough treatments in several areas, including oncology, immunology, neuroscience and cardiovascular. Guest Links: Laurens Kruidenier LinkedIn: https://www.linkedin.com/in/laurens-kruidenier-62b5a99/ Fabrice Chouraqui Linkedin: https://www.linkedin.com/in/fabricechouraqui/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Vadim Nazarov, Co-Founder and CEO of ImmunoMind, about How AI Can Help the Drug Discovery Process. Guest Bio: Vadim Nazarov is a AI and Life Sciences researcher turned startup founder. 2x founder in AI and Biotech: ImmunoMind (AI for Drug Discovery; CEO, current role) and Tensorpad (MLOps; ex-Chief AI Officer / Chief Product Officer). Built products used by three Top 5 Big Pharma and four Top 10 US universities to develop novel immunotherapies. MSc, PhD cand. in CS. Ex-senior scientist and group leader with 800+ scientific citations in AI and T-cell immunology. Alumnus of Berkeley SkyDeck, UCSF Innovation Ventures, accepted to Creative Destruction Lab. Alumni council board member at Berkeley SkyDeck. Venture Partner at emerging US-based VC fund for Life Sciences, responsible for European and Techbio / AI / AI for Drug Discovery investments. Guest Links: LinkedIn: https://www.linkedin.com/in/vdnaz/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Michelle C. Werner about how Alltrna is advancing to clinical trials a new tRNA medicine to universally treat Stop Codon Disease. Stop Codon Disease is a term that encompasses thousands of rare and common human diseases driven by the same underlying mutation -- premature termination codons (also called nonsense mutations). Approximately 10% of all people with a genetic disease have Stop Codon Disease, representing approximately 30 million people worldwide. Because of the unique biology of tRNA, Alltrna has the opportunity to scale a whole new field of genetic medicines and build a new future for patients. Guest Bio: Michelle C. Werner is a seasoned pharmaceutical executive with more than 20 years in the industry spanning both commercial and research & development (R&D) responsibilities. Prior to Alltrna, Michelle served as Worldwide Franchise Head, Solid Tumors at Novartis Oncology, where she was responsible for delivering the disease area strategies across multiple tumors and led business development efforts resulting in a doubling of long-term portfolio value for the franchise. Previous to Novartis, Michelle was a senior leader at AstraZeneca and as Global Franchise Head in Hematology, she was critical in launching multiple indications worldwide for CALQUENCE®. Outside of her corporate responsibilities, Michelle is a wife and mother to three children and is a member of the rare disease community. She is currently serving a Board appointment for the non-profit organization Rare Disease Renegades, a purpose that fuels her passions both personally and professionally. Guest Links: LinkedIn: https://www.linkedin.com/in/michelle-werner-7b30511/ Resource Links: tRNA Animation Video Alltrna Website Alltrna Twitter Flagship Pioneering Defining Stop Codon Disease The key moments in this episode are: 00:00:00 - Introduction, 00:01:02 - Michelle Werner's Career Path, 00:04:56 - Rare Disease Renegade, 00:08:23 - Flagship Pioneering, 00:12:00 - Challenges in Genetic R&D, 00:16:10 - The Potential of Genetic Driver Targeting 00:17:00 - Understanding the Role of tRNA 00:19:18 - Importance and Universality of tRNA 00:21:56 - Targeting Premature Termination Codons 00:26:33 - Alltrna's Advancement in tRNA Research 00:32:26 - The Potential of Basket Trials in Oncology Research, 00:34:21 - The Impact of Unified Clinical Trial Plans, 00:35:11 - The Funding Landscape in Biotech, 00:37:33 - Alltrna's Next Inflection Point, 00:39:33 - Building the Alltrna Team. About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Stevie Cline about Biotech Startup Investments, Investing in Regulated Spaces, and how the current economic environment is affecting deal flow. Guest Bio: Stevie Cline, J.D., L.L.M., Ph.D, is the Managing Director of Vol. 1 Ventures, an early stage venture fund focused on investing in highly regulated industries. Stevie is also the former co-founder of Prenome, a genetics-based healthcare startup focused on predicting and preventing pregnancy complications using custom diagnostic tests, AI, & machine learning. Prior to entering the tech sector, she was a well-known attorney in the M&A and Taxation space. She has also previously held leadership positions at Johns Hopkins University and the American College of Obstetricians & Gynecologists. Stevie is also the founder of Highly Regulated, a newsletter on the regulatory and compliance landscape that has over 20,000 subscribers. Guest Links: LinkedIn Twitter About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Ethan Perlstein, PhD about the Role of Families in Research Funding, 1-to-N Medicine, Clinical Trials, and the Challenges of Funding Rare Disease Research. Guest Bio: Ethan O. Perlstein received a PhD in 2006 from Harvard University (Department of Molecular and Cell Biology) while working in the laboratory of Professor Stuart Schreiber. He completed an independent postdoctoral fellowship at the Lewis-Sigler Institute at Princeton University from 2007 to 2012. Since its founding in 2014, he is CEO of Perlara PBC, the first biotech Public Benefit Corporation partnering with highly motivated families to develop treatments and cures for genetic diseases. Perlara’s first joint venture Maggie’s Pearl is the commercial sponsor of a pivotal Phase 3 trial of epalrestat for the treatment of PMM2-CDG. Guest Links: LinkedIn: https://www.linkedin.com/in/ethan-perlstein-1260545/ Twitter: https://twitter.com/eperlste Perlara Website: https://www.perlara.com/ The key moments in this episode are: 00:00:00 - Intro 00:01:25 - Background 00:03:32 - Working in Academia 00:06:17 - Unique Funding Model for Rare Diseases 00:09:44 - Collaboration with Rare Disease Families 00:15:38 - The Potential of Public Benefit Companies, 00:18:00 - The Benefits of PBCs, 00:18:31 - Personalized Medicine and DTC Biotech, 00:22:51 - One to N Approach in Personalized Medicine, 00:26:16 - Pricing for Guided Medical Attention, 00:30:00 - The Role of Foundations in Biotech Partnerships, 00:31:30 - Web Three Technologies and Patient Ownership, 00:32:31 - Financial Compensation for Clinical Trial Participants, 00:33:52 - The Potential of Web3 in Medicine, 00:38:19 - Shifting Focus to Human Trials and Patient Empowerment About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments.

Follow Vibe Bio's Socials:

Twitter

LinkedIn

Instagram

TikTok

Facebook Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Niki Markou, Director of Family Support, Marketing & Communications at Chelsea's Hope, and Jordi Duran, PhD, Principal Investigator at IQS Barcelona about Clinical Trials and the Challenges they face Funding Rare Disease Research. Watch Fighting the Rare: https://www.fightingtherare.com/ A documentary on the importance of biomedical research to find treatments for rare diseases. Fighting the Rare is a glimpse into research on Lafora disease, a rare neurodegenerative condition, through the testimonies of researchers, patients and their relatives. The key moments in this episode are: 00:00:00 - Intro 00:01:11 - Welcoming the Guests: Niki Markou and Jordi Duran, PhD 00:02:55 - What is Lafora Disease? 00:08:07 - Real-Life Experience with Lafora Disease 00:11:58 - Importance of Research and Funding for Lafora Disease 00:15:56 - Positive Progress and Diagnosis Journey, 00:18:40 - Challenges in Rare Disease Diagnosis, 00:20:06 - Genetic Testing and Birth Screening, 00:21:15 - Documentary: Fighting the Rare, 00:24:51 - Challenges and Emotional Impact on Families, 00:32:39 - The Discovery of Glycogen as the Problem in Lafora Disease, 00:33:09 - Challenges in Drug Delivery to the Brain, 00:34:27 - Similarities between Lafora Disease and Alzheimer's, 00:37:04 - Potential Impact of Lafora Disease Research on Other Neurodegenerative Conditions. Guest Bio: Niki Markou lives in Sydney, Australia and is the mother of a 19 year old girl named Angelina who has Lafora disease. She volunteers on the board of Chelsea’s Hope Lafora Children Research Fund. Previous to her daughter's diagnosis, she had a full time career in marketing. Niki joined the board in 2021, starting off as a parent advocate to help families just like her stay informed and where she still continues to be in close contact with many families around the world. Her main role has been creating all marketing content and liaise with fellow board members, researchers, doctors and organizations to create more awareness for Lafora disease and find possible treatments that could lead to a cure. Niki joined fellowships in the aim to learn about how to reduce barriers to entry into early access around the world, through learning, discussion, networking and support. Jordi Duran is a Principal Investigator and Associate Professor at Institut Químic de Sarrià (IQS) - Ramon Llull University (URL) in Barcelona. My research group is devoted to the study of brain metabolism, in particular the physiological roles of glycogen in brain functioning and its pathological role in neurodegenerative conditions like Lafora disease. Guest Links:

Chelsea's Hope Linkedin Twitter Instagram Tiktok Jordi Duran, PhD Linkedin Twitter Instagram Follow Vibe Bio's Socials: Twitter

LinkedIn

Instagram

TikTok

Facebook About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Mo Jain, MD, PhD, Founder and CEO of Sapient, about small molecule biomarkers & innovations in metabolomics. Dr. Jain is a physician-scientist with more than 20 years of expertise in physiology, biomedicine, engineering, computational biology, and mass spectrometry-based metabolomics. Prior to founding Sapient, he formed and was director of Jain Laboratory at the University of California San Diego (UCSD). There he led a multi-disciplinary research team to develop next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to probe the non-genetic landscape of disease across population-scale human studies, supported by over $30M in federal, foundation, and industry funding. Dr. Jain founded Sapient in 2021 as a spinout of Jain Laboratory to expand upon the mission of accelerating human discovery and drug development through the nexus of high throughput analytical mass spectrometry, computational biology, and population-level biomarker profiling. Dr. Jain has held faculty positions at UCSD since 2013, most recently as a Professor of Medicine and Pharmacology. He obtained his MD and PhD from Boston University School of Medicine, and performed clinical residency and fellowship training in Internal Medicine, Cardiology, and Preventative Cardiology at Brigham and Women’s Hospital, Harvard Medical School. Guest Links Linkedin: https://www.linkedin.com/in/mo-jain-md-phd-373895ba/ Sapient Twitter: https://twitter.com/SapientBio Sapient Linkedin: https://www.linkedin.com/company/sapientbio/ The key moments in this episode are: 00:00:00 - Introduction, 00:01:02 - Dr. Mo Jain's Background, 00:03:28 - Importance of Mass Spectrometry, 00:08:11 - Starting Sapient Bio, 00:10:16 - Biomarker Discovery and Therapeutic Research, 00:13:06 - Advancements in Diagnostics Technology, 00:15:05 - Constraints in the Medical Field, 00:16:44 - Future of Medicine, 00:18:12 - Collaboration with the Bill and Melinda Gates Foundation, 00:24:44 - Biotech Funding Landscape, 00:27:02 - The Importance of Profitability and Funding, 00:28:52 - Supply Chain and Manufacturing, 00:29:37 - Partnerships and Clients, 00:31:30 - Reflections on Diagnostics and Funding, 00:31:58 - Final Thoughts and Advice, Follow Vibe Bio's Socials:

• https://twitter.com/VibeBio
• https://www.linkedin.com/company/vibe-bio/
• https://www.instagram.com/vibebiotechnology/
• https://www.tiktok.com/@vibebio
• https://www.facebook.com/VibeBiotechnology/

About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Mark Kotter, PhD, Founder and CEO of bit.bio, about the Cell Therapy Crisis and the state of the Cell Therapy Field. Mark is a stem cell biologist and neurosurgeon at the University of Cambridge. Aged nineteen, he decided to pursue a career in medicine to serve others and to make a difference in people’s lives. His curiosity led him down a path of clinical service and laboratory discovery. He became fascinated by synthetic biology, as he saw it as the key to a new generation of medicines. He is the founder of bit.bio and co-founder of the cultured meat start-up Meatable.

The key moments in this episode are:
00:00:00 - Introduction,
00:01:19 - Background and Inspiration,
00:09:34 - Overview of Cell Therapy,
00:13:02 - Accelerating Drug Development,
00:16:24 - Rethinking the Paradigm,
00:18:52 - Challenges of Gene Therapy,
00:20:14 - Potential of Gene Therapy,
00:21:07 - Synthetic Biology and Cell Therapies,
00:22:59 - High Costs of Cell Therapies,
00:27:07 - Regulations and Cell Therapies,
00:37:56 - The Power of Transcription Factors,
00:39:29 - Expanding the Possibilities,
00:41:29 - The Golden Years of Biotech,
00:42:34 - Risks and Regulation,
00:43:40 - Closing Thoughts

Guest Links Linkedin: https://www.linkedin.com/in/mark-kotter-3505872a/ Twitter: https://twitter.com/MarkKotter bit.bio Links Website: https://www.bit.bio/ Linkedin: https://www.linkedin.com/company/bitbioltd/ Twitter: https://twitter.com/bitbio Follow Vibe Bio's Socials: https://twitter.com/VibeBio

https://www.linkedin.com/company/vibe-bio/

https://www.instagram.com/vibebiotechnology/

https://www.tiktok.com/@vibebio

https://www.facebook.com/VibeBiotechnology/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Court R. Turner, J.D., and Lev Becker, Ph.D., Co-Founders of Onchilles Pharma, about their novel immunotherapy, Lev's discovery of neutrophil's ELANE pathway in cancer, and biotech funding challenges/opportunities.

Guest Bio: Mr. Court Turner is cofounder and Executive Chair of Onchilles and a partner of LYZZ Capital. Mr. Turner has more than 20 years of experience in founding, operating, fundraising for, and exiting life science companies. Before joining Onchilles, Mr. Turner was a venture partner at Avalon Ventures. During his time at Avalon, he served as the founding CEO and director of both Synthorx, Inc. (acquired by Sanofi) and Cellular Approaches, Inc. Prior to those roles, Mr. Turner was the founding chairman and CEO of RQx Pharmaceuticals (acquired by Genentech). Before RQx Pharmaceuticals, he served as a member of the executive management teams at both Kalypsys, Inc. and Aurora Biosciences (acquired by Vertex Pharmaceuticals). Mr. Turner received his J.D. from the University of San Diego School of Law and a B.S. in psychology from San Diego State University. Dr. Lev Becker is cofounder and serves as a member of the board at Onchilles. He is also an Associate Professor at the University of Chicago in the Ben May Department for Cancer Research. Dr. Becker’s lab combines proteomic, bioinformatic, immunologic, and functional approaches to study innate immune cells in an unbiased manner across a spectrum of diseases and develops therapeutics to target them. His work has been published in prestigious scientific journals including Cell and Nature. Dr. Becker has received several awards for his research, including: the Duckworth Fund Commercial Promise, J Clifford Moos, and Janet Rowley Discovery Fund awards from the University of Chicago, and the Young Investigator and Fletcher Scholar awards from the Cancer Research Foundation. His lab is currently funded by the National Cancer Institute, National Institute of Diabetes and Digestive Kidney Diseases, and National Heart, Lung, and Blood Institute. He earned his Ph.D. in biochemistry from Queens University and completed his postdoctoral studies in proteomics and macrophages at the University of Washington. Guest Links: Onchilles Pharma Linkedin: https://www.linkedin.com/company/onch... Twitter: https://twitter.com/onchilles Court R. Turner, J.D. Linkedin: https://www.linkedin.com/in/court-r-t... Lev Becker, Ph.D. Linkedin: https://www.linkedin.com/in/levbecker1/ Twitter: https://twitter.com/LevBecker Follow Vibe Bio's Socials: https://twitter.com/VibeBiohttps://www.linkedin.com/company/vibe...https://www.instagram.com/vibebiotech...https://www.tiktok.com/@vibebiohttps://www.facebook.com/VibeBiotechn... About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Jacob Glanville, Founder and CEO at Centivax, about developing vaccines and funding challenges that startup companies face. This video was recorded at SynBioBeta 2023 in Oakland, CA.

Jacob Glanville is an serial entrepreneur, and computational immuno-engineer. He built and sold his first company Distributed Bio from founding in March of 2012 to a 104M dollar sale to Charles River Laboratories in December of 2020. During that period, he developed the core business model, the research teams, and the technologies that enabled Distributed Bio to become profitable without investment. As part of the acquisition agreement, he founded Centivax Inc and spun-out his assets in COVID-19 therapeutics, broad-spectrum vaccines, antivenom antibodies, anti-wound pathogen antibodies, anti-CXCR5 autoimmunity therapeutics, and blood-brain barrier translation technologies into Centivax, where he is now CEO.

He has developed multiple seminal methods in the fields of high-throughput antibody repertoire sequencing (PNAS 2009), repertoire decoding algorithms (Nature 2017), single-cell TCR receptor & phenotype sequencing (Nature Biotech, 2014), deconstructing genetic variation in the adaptive immune system (Nature Communications 2015, Nature Reports 2016, PNAS 2011, TI 2017), and computationally guided antibody library engineering (JMB 2011, JMB 2013, COSB 2015). He is the inventor of the Centivax Universal Vaccine technology, the SuperHuman discovery library technology, and the Tumbler technology. He is a Stanford University Scientific Advisory Committee member for the Sean Parker Center for Allergy and Asthma Research, a Scientific Advisory Board member for the University of San Francisco's Biotechnology program, a repeat Gates Foundation/Stanford University Computational and Systems Immunology Grant Recipient while a PhD Candidate with Mark Davis at Stanford, a Recipient of Pfizer Achievement award 2010 while Principal Scientist at Pfizer, and has been a course-founding instructor and guest lecturer for multiple graduate-level applied computational and systems immunology courses at Stanford and USF.

Guest Links

• Linkedin
• Twitter
  

Social Links

• Website⁠

• YouTube

• Twitter

• Instagram

• TikTok

• LinkedIn

• Facebook

About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Erum Azeez, Partner at Messaginglab, about Strategic Communications and Upcoming Technologies in Biotech.

⁠VibeCast YouTube⁠

Guest Links Linkedin Twitter

Social Links

• Website⁠

• YouTube

• Twitter

• Instagram

• TikTok

• LinkedIn

• Facebook

About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Neil Thanedar, Founder and GP at Utopic Ventures, about Biotech Investing and Diligence. Timestamps: 2:35: How Neil helped his dad get his first startup exit. 6:26: When Neil got involved in politics. 9:23: What bills Neil want to see passed now. 10:37: Why Neil is writing a book in public. 13:43: How to solve the funding gap in biotech. 16:09: The biggest sources of Neil's deal flow. 19:37: Why now is the best time to invest in biotech. 21:29: How early does Neil invest? 23:33: Why Neil created Utopic. 25:03: How to create the next Y Combinator. 28:11: What are red flags in biotech investing? 30:39: How Neil adds value to his startups. 35:03: Biotech 1.0 vs. Biotech 2.0 Guest Info Neil Thanedar is the founder and solo GP of Utopic Ventures, a new pre-seed VC fund that invests the first $50K-100K in biotech startups led by scientist CEOs. He was previously founding CEO of Labdoor, one of Y Combinator's first scientist-led startups, and Avomeen, a contract research lab that was acquired for $30M+ in 2016. Guest Links Linkedin: https://linkedin.com/in/thanedar Twitter: https://twitter.com/NeilThanedar Instagram: https://www.instagram.com/neilthanedar Website: https://neilthanedar.com

Social Links

• Website⁠

• YouTube

• Twitter

• Instagram

• TikTok

• LinkedIn

About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Brigitte Piniewski, MD from BlockHealth LLC about Wealthcare, Crowdfunding, & Data Ownership. Guest Info Brigitte Piniewski, MD is a physician, ex-healthcare executive, researcher, author and angel investor who has witnessed healthcare from every angle. While providing investor education in Web3 technologies, she has articulated an urgent need for health transformation and the pivotal achievements that these new technological approaches are likely to produce. To this end, Dr Piniewski advises teams and corporations via her role as a subject matter expert for Nex Cubed, a leader in early stage innovation and start-up acceleration. She has worked with international founders from Singapore, Korea and Canada as well as within the United States. Dr Piniewski received her medical degree from the University of British Columbia and McGill University, Canada and she currently resides in Portland, Oregon. YouTube About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Howard Berman, PhD (Founder and CEO) and Daniel Barvin, MBA (VP of Operations and Patient Advocacy) from Coya Theraputics, about advancements in ALS and Alzheimer's therapies. Guest Info Howard Berman, PhD: Howard co-founded Nicoya Health in 2020 to realize the vision and research of Dr. Stanley Appel and merged the company with Coya Therapeutics in 2021 where he currently serves as Chairman and CEO. He has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify, and bridge both disciplines. Howard gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie where he spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and later Eli Lilly where he was the scientific point of contact between the company and key opinion leaders for development and initiation of collaborations, clinical trials and investigator initiated trials. Howard began his career at MD Anderson Cancer Center in the technology transfer division where he was responsible for assessing the market, patent, and scientific merits of numerous oncology-based technology platforms in order to ascertain their commercial viability He received a Bachelor in Biology from the University of Michigan and a Masters and Ph.D. in Neuroscience and Pharmacology from Weill Cornell Medical School. Daniel Barvin, MBA: Daniel Barvin serves as VP, Operations and Patient Advocacy at Coya Therapeutics since 2021. Prior to joining Coya, Daniel spent his time as an advocate fighting for awareness and the rights of Presymptomatic Familial ALS patients. He started the first ever Familial ALS focused team through his work at I AM ALS. During this time, Daniel interacted with presymptomatic patients, researchers, pharma executives, and advocacy organizations. In addition, Daniel has held operations and design positions at Morgan Stanley, Dril-Quip and GE. Daniel received his B.S. in Mechanical Engineering from Case Western and his M.B.A from Rice University. Guest Links https://twitter.com/CoyaTx

https://www.linkedin.com/in/howard-berman-phd-8b19681b8/

https://twitter.com/FamilialALS

https://www.linkedin.com/in/daniel-barvin-mba-8b25bb24/

Follow Vibe Bio's Socials:

• ⁠Website⁠⁠

• ⁠YouTube⁠

• ⁠Twitter⁠

• ⁠Instagram⁠

• ⁠TikTok⁠

• ⁠LinkedIn⁠

• ⁠Facebook⁠

About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Wendy Charles, Chief Scientific Officer at BurstIQ, about the how and why Real World Data (RWD) is important to healthcare and research. Wendy shares her insights on sources of RWD, ownership, privacy, and how web3 is disrupting the way the healthcare industry deals with health data. Guest Info Dr. Wendy Charles has been involved in clinical trials from every perspective for 30 years, with a strong background in operations and regulatory compliance. She currently serves as Chief Scientific Officer for BurstIQ, a digital health transformation company specializing in blockchain and AI. She is also an adjunct faculty member at the University of Colorado, Denver and at the University of Denver where she teaches Health Information Technology. Dr. Charles currently serves on the European Union Blockchain Observatory and Forum Expert Panel, HIMSS Blockchain Task Force, Government Blockchain Association healthcare group, and IEEE Blockchain working groups. She is also involved as an assistant editor and reviewer for academic journals. Dr. Charles obtained her Ph.D. in Clinical Science with a specialty in Health Information Technology from the University of Colorado, Anschutz Medical Campus. She is certified as an IRB Professional, Clinical Research Professional, and Blockchain Professional. Guest Links LinkedIn Blockchain in Life Sciences Book edited Wendy Charles, PhD

Follow Vibe Bio's Socials:

• ⁠Website⁠⁠

• ⁠YouTube⁠

• ⁠Twitter⁠

• ⁠Instagram⁠

• ⁠TikTok⁠

• ⁠LinkedIn⁠

• ⁠Facebook⁠

About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Gina Zanik, Co-Founder and Executive Director of Rare and Undiagnosed Network. Gina Zanik (Szajnuk) started her career in the entertainment industry. She worked in Hollywood for over ten years. She supported movie directors, producers, actors, literary agents and executives. She entered the world of the NBA and NFL and served as Director of Client Services and Executive Assistant to the CEO at Priority Sports & Entertainment in Chicago. She supported the President of Basketball Operations at U1st Sports, an NBA and European basketball agency. She worked in corporations supporting VP, President, and CEO level executives for five years in Los Angeles and Manhattan. She now serves as the Co-founder and Executive Director for the Rare and Undiagnosed Network (RUN), a 501©3 nonprofit organization in Salt Lake City formed in 2014. Her three children, each of whom live with a chronic, invisible, and undiagnosed rare disease, continue to inspire, and motivate her to empower patients and their families with genomic information and community through advocacy, networking, and support. Gina is also living with a chronic, invisible, and undiagnosed rare disease. She is the Vice-Chair of the Utah Rare Disease Advisory Council (RDAC). She is a Board Member of the Metrodora Institute’s Foundation. She is a member of the Undiagnosed Disease Network International (UDNI). She serves as a Patient Advocacy Advisor on RARE-X. In 2016, Gina was the Chair of Utah Rare and was on the Executive Committee for four years. Gina continuously works to build a network of rare advocates, geneticists, researchers, specialists, and volunteers who can come together under one platform. In 2016, RUN started the international Undiagnosed Rare Disease Day (Undiagnosed Day) awareness campaign on April 29th. She was a member of the Participant Engagement and Empowerment Resource (PEER) of the Undiagnosed Diseases Network (UDN) for two years. She served as the National Organization for Rare Disorders (NORD) as their Utah State Ambassador and then as their Undiagnosed Advocacy Ambassador for four years. She is a public speaker and published writer. In 2016, Gina won the Rare Voice Award from the EveryLife Foundation for Rare Diseases as well as accepted the Rare Champion of Hope – Advocacy Award from Global Genes. She is married to Justin Zanik, the NBA Utah Jazz General Manager. Gina has brought awareness to the public about the importance of undiagnosed and rare diseases through RUN’s NBA Initiative started in 2015. She was born and raised in Madison, WI. She graduated with a Bachelor of Arts from the University of Wisconsin – Madison. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials:

• ⁠Website⁠⁠

• ⁠YouTube⁠

• ⁠Twitter⁠

• ⁠Instagram⁠

• ⁠TikTok⁠

• ⁠LinkedIn⁠

• ⁠Facebook⁠

Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with JennyCo Founders Jenny Diggles and Michael Nova about owning your own health data in Web3 & privacy preserving technology. Michael Nova - LinkedIn

JennyCo - Twitter

VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio:

• Website⁠⁠

• ⁠YouTube⁠

• ⁠Twitter⁠

• ⁠Instagram⁠

• ⁠TikTok⁠

• ⁠LinkedIn⁠

• ⁠Facebook⁠

In this episode, VibeCast host Ray Dogum speaks with Nadim Yacteen, a Managing Partner at Recombinators, about his experience teaching Precedent Driven Innovation in Biotech. 00:00:00 - Introduction 00:01:30 - Journey into Innovation 00:10:12 - How Innovation Happens 00:16:25 - Precedent Driven Innovation 00:15:37 - Approach for Strategic Innovation 00:18:19 - Key Learnings 00:21:10 - Process Innovation 00:29:20 - AI and Innovation 00:30:24 - Broken Healthcare System 00:34:17 - Regulatory Hurdles 00:40:36 - Patient-Centered Innovation 00:45:33 - Psychedelics in Medicine 00:47:57 - Biotech Funding Landscape 00:51:20 - Final Thoughts VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders, investors, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials:

• ⁠Website⁠⁠

• ⁠YouTube⁠

• ⁠Twitter⁠

• ⁠Instagram⁠

• ⁠TikTok⁠

• ⁠LinkedIn⁠

• ⁠Facebook⁠

Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Gunnar Esiason, MBA MPH. Gunnar is currently a principal at Florence Healthcare. He shares his experience as a Cystic Fibrosis (CF) patient/advocate, fundraising with his father Boomer Esiason at the Boomer Esiason Foundation, and the current state of CF Clinical Trials. Gunnar's Socials: https://twitter.com/G17Esiason www.instagram.com/esiason17g Website: www.GunnarEsiason.com 00:00:00 - Introduction 00:01:25 - About Gunnar's Experience with Cystic Fibrosis 00:08:01 - Public Visibility of CF Advocacy 00:11:36 - Cystic Fibrosis Fundraising 00:14:01 - Patient Connection to Sponsors in Clinical Trials 00:14:44 - Running Out of Options 00:16:14 - Participating in a Clinical Trial 00:19 :28 - Trikafta and Rare Mutations 00:22:34 - Renewed Prescription to Life 00:26:34 - Improving the Consent Process 00:29:36 - Development of Cystic Fibrosis Treatments 00:32:49 - Trikafta Baby Boom and IVF Grants 00:35:17 - Cystic Fibrosis Drug Pipeline 00:37:20 - Battle Against Rare Disease Medications 00:44:58 - Market Price of Trikafta 00:45:19 - Social Contract Between Biotech and Insurance Industry 00:46:10 - Concerns About Antibacterial Resistance 00:50:14 - Future Goals and Plans for Advocacy Work 00:51:29 - Final Thoughts VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests include biotech founders,investors,  regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Christopher Moxham, Chief Science Officer at Rarebase, about Drug Hunting, Genetics Research, and the Drug Discovery Landscape. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments.

Follow Vibe Bio's Socials:

• ⁠Website⁠⁠

• ⁠YouTube⁠

• ⁠Twitter⁠

• ⁠Instagram⁠

• ⁠TikTok⁠

• ⁠LinkedIn⁠

• ⁠Facebook⁠

Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Cognitive Neuroscientist and Researcher Sarah Hamburg, about Neuroscience Research and DeSci.

Sarah is a Postdoctoral Research Fellow in Neuromorphic Computing (focusing on developmental neurorobotics), and an Industry Associate at UCL's Centre for Blockchain Technologies. Her academic background is in Neuroscience and Psychology, and between her PhD and postdoc she worked in FinTech R&D and Innovation for several years, before becoming involved in the Decentralised Science (DeSci movement).

VibeCast by Vibe Bio is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Vibe Bio seeks to find every cure for every community.  We see a future where communities of biopharma experts & patients can collaborate to identify high-potential medicines and access capital on-demand to develop them.

Guests include biotech founders, investors, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments.

Follow Vibe Bio:

• ⁠⁠Website⁠⁠⁠

• ⁠⁠YouTube⁠⁠

• ⁠⁠Twitter⁠⁠

• ⁠⁠Instagram⁠⁠

• ⁠⁠TikTok⁠⁠

• ⁠⁠LinkedIn⁠⁠

• ⁠⁠Facebook⁠⁠

Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.

In this episode, VibeCast host Ray Dogum speaks with Everlum Bio Founders Rick Barkley and Casey McPherson, about Rare Disease Drug Development, Incentives, and Personalized Medicine.

Casey McPherson has spent the last 25 years as a singer-songwriter, entrepreneur, and mental health advocate. His bands, Alpha Rev and Flying Colors, have toured the world and had songs hit the Top 10 charts. However, in 2019, his world changed forever when his daughter, Rose, was diagnosed with a rare genetic disease with no cure: HNRNPH2. Two years later, after hundreds of meetings with researchers, scientists, and biotech companies, he started To Cure a Rose Foundation to develop a therapeutic for Rose, and children like her. Thanks to the hope offered by recent scientific breakthroughs, Casey is on a mission to save his daughter and change the way we treat children across the rare disease spectrum. Marrying his two passions, Casey uses music to spread awareness and raise money for rare disease treatments. In 2022, he co-founded Everlum Bio – the first ever rare disease drug development lab for family foundations. He lives in Austin, Texas with his two beautiful children.

VibeCast by Vibe Bio is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Vibe Bio seeks to find every cure for every community.  We see a future where communities of biopharma experts & patients can collaborate to identify high-potential medicines and access capital on-demand to develop them.

Guests include biotech founders, investors, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments.

Follow Vibe Bio:

• ⁠Website⁠⁠

• ⁠YouTube⁠

• ⁠Twitter⁠

• ⁠Instagram⁠

• ⁠TikTok⁠

• ⁠LinkedIn⁠

• ⁠Facebook⁠

Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and guests do not necessarily reflect any agency, organization, or company that they work for.